CE PANEL VIDEO
As the use of oral oncolytics increases, cancer programs face a number of challenges to ensure high-quality care for their patients. In this video, a panel of leading experts in oncology practice discuss the key issues involved in patient adherence to oral therapeutics, including awareness, education and communication.
PANELISTS
Kimberly M. Hicks, PharmD, MHA (Moderator)
Director of Pharmacy Services at HHCS Health Group of Companies, Orlando, Florida
John Novak, CHA, PA-C
Physician Assistant at Rocky Mountain Cancer Centers, and clinical preceptor at University of Colorado School of Medicine, Aurora, Colorado
Susan Scherer, RN, BSN, OCN
CEO and founder of RN Cancer Guides Solutions in Tampa, Florida
Diane Cope, PhD, ARNP-BC, AOCNP
Oncology nurse practitioner at Florida Cancer Specialists and Research Institute, Ft. Myers, Florida
Access Supplement
THE ROLE OF THE ADVANCED PRACTITIONER IN MAINTAINING ADHERENCE IN PATIENTS ON ORAL ONCOLYTICS
Based on the panel discussion, this supplement to JADPRO centers on the role of the advanced practitioner in maintaining adherence in patients on oral oncolytics. Case studies illustrate common challenges to non-adherence, and steps to successful implementation of oral oncolytics are reviewed.
Download Patient Guide
PATIENT EDUCATION
Helping patients adhere to their often-complicated regimens of oral oncolytics begins and ends with communication. Share this resource with your patients as a way to start the conversation about which strategies for adherence will work best for them.
Download Table
TABLE OF ORAL AGENTS USED IN THE TREATMENT OF CANCER
As the number of available oral oncolytics increases rapidly, it becomes more and more important for advanced practitioners to stay current on the medications their patients may be prescribed. This table of over 80 oral agents provides a starting point for keeping up with new approvals.
View Resources
ONLINE RESOURCES
Here you'll find a collection of articles and websites to help you learn more about ways you can support your patients taking oral oncolytics.
This CME/CE/CPE certified activity is jointly provided by
